The global Drug Discovery Informatics Market is expected to reach USD 2.8 billion in 2025 and is projected to register a CAGR of 8.4% during the forecast period. Surgical sealants are materials used to permanently seal wounds, surgical incisions, and other tissue. They are used to close wounds, repair surgical incisions, and to prevent leakage of fluids and gases.
The increasing prevalence of chronic diseases, rising demand for minimally invasive surgeries, and technological advancements in wound closure technology are the major factors driving the growth of the global Drug Discovery Informatics Market. The rising geriatric population and the increasing awareness of new technologies are also expected to further boost the market growth.
Currently, Drug Discovery Informatics Market is expected to reach USD 2.8 billion in 2025 from USD 1.9 billion in 2020, at a CAGR of 8.4% during the forecast period. Growth in this market is driven by the growing prevalence and incidence rates of various disorders such as obesity and CVDs; increasing incidence of trauma; and growth in the number of accidents and sports-related injuries, which has led to an increase in surgical procedures being performed across the globe. Also, the need to manage blood loss in patients and R&D being undertaken to bring innovative products to the market is aiding the market growth. Better cosmetic outcomes are also increasing their adoption in cosmetic procedures across the globe.
The Drug Discovery Informatics Market is segmented by product type, application, end-user, and region. On the basis of product type, the market is divided into natural sealants, synthetic sealants, and others. Natural sealants are derived from naturally occurring substances, including collagen, fibrin, and albumin. Synthetic sealants are made from synthetic materials, such as polyethylene glycol and polyvinyl alcohol.
Request for assumptions & how numbers were triangulated.
By function, the sequencing and target data analysis segment accounted for the largest share for the drug discovery informatics market.
The sequencing and target data analysis segment accounted for the largest share of the drug discovery informatics market for the function segment of the market in 2019. The large share of this segment can be attributed to increased application for sequencing analysis for the new drug entity and ease of handling of information from different sources and different domains.
By the end-user, the pharmaceutical companies segment accounted for the largest share of the drug discovery informatics market.
The pharmaceutical companies segment accounted for the largest share of the drug discovery informatics market in 2019, and pharmaceutical companies are using these informatics software extensively for pre-clinical research & development, target identification, compound screening and lead identification, and streamlining their drug discovery process which is the major factor for driving the growth of this segment
By application, the drug development segment accounted for the largest share of the drug discovery informatics market.
The drug development segment accounted for the largest share of the drug discovery informatics market in 2019, large share of this segment is primarily attributed to the increasing investments in the research and development of new drug molecules and the growing need for time and cost optimization for drug discovery and development.
The major companies in the drug discovery informatics market include Jubilant Life Sciences Limited (India), Charles River Laboratories (US), IBM (US), Clarivate Analytics (US), and Accenture (Ireland). These players have adopted various growth strategies such as product launches, acquisitions, to increase their presence in the global drug discovery informatics market.
Download an Illustrative Overview:
- In May 2019, Jubilant selected the CDD Vault informatics platform as its discovery research informatics platform for five years
- In May, 2019, Dassault Systemes acquired Medidata Solution adding its& clinical expertise and cloud-based solutions to Dassault’s portfolio
- In September 2019 Evotec collaborated with Takeda Pharmaceutical Company Limited to establish five drug discovery programs with clinical candidates from Evotec for further clinical development by Takeda across multiple therapy areas